相关实验视频

Updated: May 5, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

开发一个延长作用的 fostemsavir 脂质纳米颗粒

Farhana Islam^1,2, Srijanee Das^1,3, Md Ashaduzzaman⁴

¹Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.

Communications biology

|July 30, 2024

概括

一种新的脂质纳米粒子 (LNP) 配方的fostemsavir (FTR) 通过在巨细胞中创建药物储存,延长药物停留时间和增强抗逆转录病毒活性,有效地预防HIV-1感染.

科学领域:

纳米医学是一种纳米医学.
病毒学病毒学
药理学药理学是指药理学的学科.

背景情况:

人类免疫缺陷病毒1型 (HIV-1) 仍然是一个重大的全球卫生挑战.
目前的抗逆转录病毒疗法需要患者始终坚持治疗,才能有效.
开发长效配方可以改善治疗坚持性和治疗结果.

研究的目的:

开发和表征一种扩展作用的脂质纳米粒子 (LNP) 配方的 fostemsavir (FTR).
评估FTR-LNP配方的物理化学特性及其对抗逆转录病毒活性的影响.
评估FTR-LNP在预防HIV-1感染方面的潜力.

主要方法:

在脂质纳米颗粒 (LNP) 中形成的 fostemsavir (FTR) 配方,具有不同的 PEGylated 脂质组成.
描述LNP的物理化学性质,包括大小,多分散性,形状和泽塔潜力.
在实验室中评估药物的细胞内化,液体流下的稳定性,以及对HIV-1的抗逆转录病毒疗效.

主要成果:

通过在巨细胞中建立药物储存库,FTR-LNP配方证明了延长的血停留时间.
物理化学性质,受PEGylated脂质组成和流速的影响,与改善的抗逆转录病毒活性相关.
FTR-LNP配方表现出增强的药物颗粒稳定性和细胞内化,从而产生有效的抗逆转录病毒疗效.

结论:

延长作用的 fostemsavir (FTR) 脂质纳米粒子 (LNP) 配方在预防HIV-1感染方面表现有前途.
FTR-LNP的物理化学特性对于它们增强的抗逆转录病毒活性和延长药物作用至关重要.
这种基于LNP的药物输送系统为长效的HIV-1预防和治疗提供了潜在的战略.

更多相关视频

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

相关概念视频

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.